Literature DB >> 12887097

Modulation of regulatory T cell immunity by the neuropeptide alpha-melanocyte stimulating hormone.

A W Taylor1.   

Abstract

Although many immunosuppressive factors have been identified in the eye, one of these factors, alpha-melanocyte stimulating hormone (alpha-MSH), both suppresses the activation of inflammatory activity by primed T cells and induces the activation of regulatory T cells (Treg cells). This neuropeptide alone at its ocular physiological concentration can account for most of the immunosuppressive activity of aqueous humor (the fluid filing the anterior chamber of the eye). Aqueous humor made devoid of alpha-MSH no longer suppresses IFN-gamma production by Th1 cells. It is alpha-MSH that mediates aqueous humor induction of regulatory T cells. What we have found is that alpha-MSH mediates the induction of C4+ CD25+ Treg cells, and that if the alpha-MSH Treg cells are specific to an autoantigen they can be used to suppress autoimmune disease. It is the objective of this review to demonstrate how we came to discover that alpha-MSH could have such an important role in the extreme regional immunity of the immune privileged eye and how this discovery could be applied to create or reestablish tolerance to prevent autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12887097

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  13 in total

Review 1.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

2.  RRAS: A key regulator and an important prognostic biomarker in biliary atresia.

Authors:  Rui Zhao; Hao Li; Chun Shen; Shan Zheng
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

3.  The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages.

Authors:  A W Taylor
Journal:  J Neuroimmunol       Date:  2005-05       Impact factor: 3.478

Review 4.  Applications of the role of α-MSH in ocular immune privilege.

Authors:  Andrew W Taylor; Darren Lee
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

5.  Ascorbate in aqueous humor augments nitric oxide production by macrophages.

Authors:  Kyle C McKenna; Kelly M Beatty; Rebecca C Scherder; Fuwang Li; Huanbo Liu; Alex F Chen; Arnab Ghosh; Dennis J Stuehr
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

6.  Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection.

Authors:  Pedram Hamrah; Zdenka Haskova; Andrew W Taylor; Qiang Zhang; Bruce R Ksander; M Reza Dana
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

7.  Hypophysectomy and neurointermediate pituitary lobectomy reduce serum immunoglobulin M (IgM) and IgG and intestinal IgA responses to Salmonella enterica serovar Typhimurium infection in rats.

Authors:  Rafael Campos-Rodríguez; Andrés Quintanar-Stephano; Rosa Adriana Jarillo-Luna; Gabriela Oliver-Aguillón; Javier Ventura-Juárez; Victor Rivera-Aguilar; Istvan Berczi; Kalman Kovacs
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

8.  Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis.

Authors:  D J Lee; D J Biros; A W Taylor
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

9.  Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

10.  The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy.

Authors:  Andrew W Taylor; Nobuyoshi Kitaichi
Journal:  Brain Behav Immun       Date:  2008-01-02       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.